BRKR:NSD-Bruker Corporation (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 67.71

Change

+0.55 (+0.82)%

Market Cap

USD 10.18B

Volume

0.54M

Average Target Price

USD 60.86 (-10.12%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+19.88 (+3.33%)

USD47.18B 26.60 98.00
PODD Insulet Corporation

+1.71 (+0.60%)

USD18.77B 2,834.80 179.30
ABMD Abiomed, Inc

+12.54 (+3.80%)

USD14.90B 75.09 58.30
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
IART Integra LifeSciences Holdings ..

+1.63 (+2.24%)

USD6.15B 46.32 25.93
TNDM Tandem Diabetes Care, Inc

+1.40 (+1.51%)

USD5.81B N/A N/A
SWAV ShockWave Medical, Inc

+13.90 (+9.96%)

USD4.89B N/A N/A
LIVN LivaNova PLC

+1.62 (+1.99%)

USD3.96B 77.40 N/A
SDC SmileDirectClub, Inc

+0.34 (+3.46%)

USD3.92B N/A N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing BRKR

Symbol Name Weight Mer Price(Change) Market Cap
RNMC First Trust Mid Cap US Eq.. 0.00 % 0.60 %

+0.42 (+1.49%)

USD0.02B
LSAF LeaderSharesTM AlphaFacto.. 0.00 % 0.75 %

+0.33 (+1.04%)

USD0.08B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.09% 65% D 76% C
Dividend Return 0.07% 100% A+ 3% F
Total Return 25.16% 65% D 75% C
Trailing 12 Months  
Capital Gain 91.27% 65% D 67% D+
Dividend Return 0.45% 100% A+ 5% F
Total Return 91.72% 65% D 67% D+
Trailing 5 Years  
Capital Gain 136.42% 71% C- 74% C
Dividend Return 2.79% 100% A+ 6% F
Total Return 139.21% 71% C- 74% C
Average Annual (5 Year Horizon)  
Capital Gain 22.08% 54% F 72% C-
Dividend Return 0.52% 100% A+ 12% F
Total Return 22.59% 56% F 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 25.13% 91% A- 65% D
Risk Adjusted Return 89.92% 99% A+ 91% A-
Market Capitalization 10.18B 96% A 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 65.84 29% F 18% F
Price/Book Ratio 10.67 30% F 16% F
Price / Cash Flow Ratio 30.64 16% F 15% F
EV/EBITDA 32.31 57% F 30% F
Management Effectiveness  
Return on Equity 16.88% 94% A 88% B+
Return on Invested Capital 11.18% 93% A 83% B
Return on Assets 5.72% 93% A 86% B
Debt to Equity Ratio 87.63% 27% F 25% F
Technical Ratios  
Short Ratio 4.55 37% F 23% F
Short Percent 2.83% 72% C- 56% F
Beta 1.30 44% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector